WordNet

abnormality in performing voluntary muscle movements

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/04/12 15:18:02」(JST)

wiki en

Dyskinesia refers to a category of movement disorders that are characterized by involuntary muscle movements,^[1] including movements similar to tics or chorea and diminished voluntary movements.^[2] Dyskinesia can be anything from a slight tremor of the hands to an uncontrollable movement of the upper body or lower extremities. Discoordination can also occur internally especially with the respiratory muscles and it often goes unrecognized.^[3] Dyskinesia is a symptom of several medical disorders that are distinguished by their underlying cause.

Types

Medication-induced dyskinesias

Acute dystonia is a sustained muscle contraction that sometimes appears soon after administration of antipsychotic medications.^[4] Any muscle in the body may be affected, including the jaw, tongue, throat, arms, or legs. When the throat muscles are involved, this type of dystonia is called an acute laryngospasm and is a medical emergency because it can impair breathing.^[4] Older antipsychotics such as Haloperidol or Fluphenazine are more likely to cause acute dystonia than newer agents. Giving high doses of antipsychotics by injection also increases the risk of developing acute dystonia.^[4]

Levodopa-induced dyskinesia (LID) is evident in patients with Parkinson's disease who have been on levodopa (L‑DOPA) for prolonged periods of time. LID commonly first appears in the foot, on the most affected side of the body. There are three main types that can be classified on the basis of their course and clinical presentation following an oral dose of L‑DOPA:^[5]^[6]

Off-period dystonia – correlated to the akinesia that occurs before the full effect of L‑DOPA sets in, when the plasma levels of L‑DOPA are low. In general, it occurs as painful spasms in the foot. Patients respond to L‑DOPA therapy.^[5]^[6]
Diphasic dyskinesia – occurs when plasma L-DOPA levels are rising or falling. This form occurs primarily in the lower limbs (though they can happen elsewhere) and is usually dystonic (characterized by apparent rigidity within muscles or groups thereof) or ballistic (characterized by involuntary movement of muscles) and will not respond to L‑DOPA dosage reductions.^[5]^[6]
Peak-dose dyskinesia – the most common form of levodopa-induced dyskinesia; it correlates with the plateau L‑DOPA plasma level. This type usually involves the upper limbs more (but could also affect the head, trunk and respiratory muscles), is choreic (of chorea), and less disabling. Patients will respond to L‑DOPA reduction but may be accompanied by deterioration of parkinsonism.^[5]^[6] Peak-dose L-DOPA-induced dyskinesia has recently^[update] been suggested to be associated with cortical dysregulation of dopamine signaling.^[7]

Chronic/tardive

Late-onset dyskinesia, also known as tardive dyskinesia, occurs after long-term treatment with an antipsychotic drug such as haloperidol (Haldol) or amoxapine (Asendin). The symptoms include tremors and writhing movements of the body and limbs, and abnormal movements in the face, mouth, and tongue – including involuntary lip smacking, repetitive pouting of the lips, and tongue protrusions.^[8]

Rabbit syndrome is another type of chronic dyskinesia, while orofacial dyskinesia may be related to persistent replication of Herpes simplex virus type 1.^[9]

Non-motor

Two other types, primary ciliary dyskinesia and biliary dyskinesia, are caused by specific kinds of ineffective movement of the body, and are not movement disorders.

Spastic thrusting of hip area can occur in Sodemytopic Parkinson's.^[jargon]

References

^ "Dyskinesia (Health Article)". Yahoo! Health. Retrieved 25 January 2014.
^ "dyskinesia" at Dorland's Medical Dictionary
^ Healy 2008, p. 29-30.
^ ^a ^b ^c al.], edited by Brian K. Alldredge ... [et (2013). Applied therapeutics : the clinical use of drugs. (10th ed.). Baltimore: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 1937. ISBN 978-1609137137.
^ ^a ^b ^c ^d Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (April 2007). "Levodopa-induced dyskinesias". Movement Disorders Society 22 (10): 1379–89. doi:10.1002/mds.21475. PMID 17427940.
^ ^a ^b ^c ^d Thanvi B, Lo N, Robinson T (June 2007). "Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment". Postgraduate Medical Journal 83 (980): 384–88. doi:10.1136/pgmj.2006.054759. PMC 2600052. PMID 17551069. Retrieved 30 November 2013. (full free text)
^ Halje P, Tamtè M, Richter U, Mohammed M, Cenci MA, Petersson P (November 2012). "Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations". Journal of Neuroscience 32 (47): 16541–51. doi:10.1523/JNEUROSCI.3047-12.2012. PMID 23175810. Retrieved 30 November 2013. (full free text)
^ Healy 2008, p. 30-31.
^ Gonzales GR (July 1992). "Postherpes simplex type 1 neuralgia simulating postherpetic neuralgia". J Pain Symptom Manage 7 (5): 320–3. doi:10.1016/0885-3924(92)90065-p. PMID 1624816.

Works cited

David Healy (3 December 2008). Psychiatric Drugs Explained. Elsevier Health Sciences. ISBN 978-0-7020-2997-4. Retrieved 16 December 2010.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 遅発性ジスキネジア：臨床的特徴および診断 tardive dyskinesia clinical features and diagnosis
2. パーキンソン病における症状の変動およびジスキネジア motor fluctuations and dyskinesia in parkinson disease
3. 遅発性ジスキネジア：予防および治療 tardive dyskinesia prevention and treatment
4. ジストニアの分類および評価 classification and evaluation of dystonia
5. 遅発性ジスキネジア：病因および疫学 tardive dyskinesia etiology and epidemiology

English Journal

Clinical value of measurement of pulmonary radioaerosol mucociliary clearance in the work up of primary ciliary dyskinesia.

Munkholm M1, Nielsen KG, Mortensen J.
EJNMMI research.EJNMMI Res.2015 Dec;5(1):118. doi: 10.1186/s13550-015-0118-y. Epub 2015 Jul 16.
BACKGROUND: We aimed to evaluate and define the general clinical applicability and impact of pulmonary radioaerosol mucociliary clearance (PRMC) on the work up of patients suspected of having primary ciliary dyskinesia (PCD). In addition, we wanted to evaluate the accuracy of the reference values us
PMID 26179226

Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses.

Frye MA1, McElroy SL, Fuentes M, Sutor B, Schak KM, Galardy CW, Palmer BA, Prieto ML, Kung S, Sola CL, Ryu E, Veldic M, Geske J, Cuellar-Barboza A, Seymour LR, Mori N, Crowe S, Rummans TA, Biernacka JM.
International journal of bipolar disorders.Int J Bipolar Disord.2015 Dec;3(1):30. doi: 10.1186/s40345-015-0030-4. Epub 2015 Jun 24.
BACKGROUND: We aimed to establish a bipolar disorder biobank to serve as a resource for clinical and biomarker studies of disease risk and treatment response. Here, we describe the aims, design, infrastructure, and research uses of the biobank, along with demographics and clinical features of the fi
PMID 26105627

Severe brittle dyskinesias following DBS battery replacement.

Rizzi M1, Romito LM, Messina G, Franzini A.
Acta neurochirurgica.Acta Neurochir (Wien).2015 Sep;157(8):1441-2. doi: 10.1007/s00701-015-2482-9. Epub 2015 Jun 25.
PMID 26108635

Japanese Journal

症例 60歳代で発症したprimary ciliary dyskinesiaの1例

中本啓太郎,高柳昇,河手絵理子 [他]
日本呼吸器学会誌 = Annals of the Japanese Respiratory Society 2(6), 841-845, 2013-11-10
NAID 40019893020

原発性線毛運動不全症（PCD）における耳鼻咽喉科医の役割

大原浩達,田中秀峰,米納昌恵 [他],原晃
耳鼻咽喉科臨床 106(4), 347-353, 2013
… Primary ciliary dyskinesia (PCD) is a rare, autosomal recessive disease with abnormalities of the ciliary structure and function, which causes impaired mucociliary clearance. …
NAID 130003374049

Evaluation of the Efficacy of Pramipexole for Treating Levodopa-induced Dyskinesia in Patients with Parkinson's Disease

Utsumi Hiroya,Okuma Yasuyuki,Kano Osamu,Suzuki Yutaka,Iijima Mutsumi,Tomimitsu Hiroyuki,Hashida Hideji,Kubo Shin-ichiro,Suzuki Masahiko,Nanri Kazunori,Matsumura Miyuki,Murakami Hidetomo,Hattori Nobutaka
Internal Medicine 52(3), 325-332, 2013
… Objective The long-term use of levodopa to treat Parkinson's disease (PD) is often limited by the development of motor complications (e.g. levodopa-induced dyskinesia, LID). … Dyskinesia was evaluated using Core Assessment Program for Surgical Interventional Therapies scores. …
NAID 130003365866

Related Pictures

★リンクテーブル★

リンク元	「片側バリズム」「遅発性ジスキネジア」「ジスキネジア」「asterixis」「movement disorder」
拡張検索	「ciliary dyskinesia」「drug-induced dyskinesia」「medication-induced dyskinesia」

「片側バリズム」

Dyskinesia
Classification and external resources
Specialty	Neurology
ICD-10	G24.9
ICD-9-CM	333.8
DiseasesDB	17912
Patient UK	Dyskinesia
MeSH	D020820
	[edit on Wikidata]

　　[★]

英: hemiballism、
ラ: hemiballismus
関: ジスキネジア、不随意運動、固定姿勢保持困難、異常運動、ヘミバリズム、バリズム; abnormal movement、asterixis、ballismus、dyskinesia、hemiballismus、involuntary movement

上下肢の激しい運動が体の半側に出現する状態

「遅発性ジスキネジア」

　　[★]

英: tardive dyskinesia
同: 遅発性ジスキネジー
関: ジスキネジア dyskinesia

[show details]

遅発性ジスキネジア : 約 11,000 件
晩発性ジスキネジア : 10 件
遅発性ジスキネジー : 約 17,500 件

「ジスキネジア」

　　[★]

英: dyskinesia, dyskinesis
関: ジスキネジー

<youtube>http://www.youtube.com/watch?v=2TU2s3VxEI4</youtube> <youtube>http://www.youtube.com/watch?v=d1jJyk_poqE</youtube>

「asterixis」

　　[★]

固定姿勢保持困難(羽ばたき振戦)

関: abnormal movement、ballismus、dyskinesia、hemiballism、hemiballismus、involuntary movement

「movement disorder」

　　[★] 運動障害、運動異常症

関: dyskinesia、dyskinesis、dyskinetic、dysmotility、oral dyskinesia、orofacial dyskinesia

「ciliary dyskinesia」

　　[★] 線毛機能不全、線毛機能不全症

関: ciliary motility disorder、immotile cilia syndrome

「drug-induced dyskinesia」

　　[★]

薬物性ジスキネジア、薬剤誘発ジスキネジア

関: medication-induced dyskinesia

「medication-induced dyskinesia」

　　[★]

薬剤誘発ジスキネジア

関: drug-induced dyskinesia

[1] "Dyskinesia (Health Article)". Yahoo! Health. Retrieved 25 January 2014.

[2] "dyskinesia" at Dorland's Medical Dictionary

[FOOTNOTEHealy200829-30-3] Healy 2008, p. 29-30.

[Applied_Therapeutics_Acute_Dystonia-4] .], edited by Brian K. Alldredge ... [et (2013). Applied therapeutics : the clinical use of drugs. (10th ed.). Baltimore: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 1937. ISBN 978-1609137137.

[Fabbrini-5] Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (April 2007). "Levodopa-induced dyskinesias". Movement Disorders Society 22 (10): 1379–89. doi:10.1002/mds.21475. PMID 17427940.

[Thanvi-6] Thanvi B, Lo N, Robinson T (June 2007). "Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment". Postgraduate Medical Journal 83 (980): 384–88. doi:10.1136/pgmj.2006.054759. PMC 2600052. PMID 17551069. Retrieved 30 November 2013. (full free text)

[Tamte-7] Halje P, Tamtè M, Richter U, Mohammed M, Cenci MA, Petersson P (November 2012). "Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations". Journal of Neuroscience 32 (47): 16541–51. doi:10.1523/JNEUROSCI.3047-12.2012. PMID 23175810. Retrieved 30 November 2013. (full free text)

[FOOTNOTEHealy200830-31-8] Healy 2008, p. 30-31.

[Gonazales-9] Gonzales GR (July 1992). "Postherpes simplex type 1 neuralgia simulating postherpetic neuralgia". J Pain Symptom Manage 7 (5): 320–3. doi:10.1016/0885-3924(92)90065-p. PMID 1624816.

匿名

検索

案内

案内

dyskinesia